Takeda, the Japanese pharmaceutical company, has outlined its business strategy focused on developing gastroenterology treatments and addressing rare diseases, such as hemophilia, oncology and vaccines. The company believes this direction is where its innovation is most needed and where it foresees significant growth.
Hernán Porcille, general director of Takeda in Mexico, revealed in an interview with MILENIO that they have launched 10 new highly specialized products since 2021 and seek to consolidate their market presence before 2030.
Takeda aims to steadily increase the number of patients served in Mexico at a double-digit rate.
Porcille highlighted that Mexico is one of Takeda's five main emerging markets and that the country is at the forefront of pharmaceutical product launches. The company has focused on innovative treatments, including oncology drugs for lung cancer, treatments for short bowel syndrome and a dengue vaccine in regulatory process.
In 2021, it has already launched products to treat hemophilia A and gastrointestinal diseases such as Crohn's disease and ulcerative colitis, among others. The company faces the usual regulatory timelines, especially for such specific and highly specialized molecules.
In the case of its dengue vaccine, it is expected to be authorized in Mexico within two years. In 2023, the company inaugurated its innovation center in Santa Fe, its second innovation center in the world, taking advantage of Mexico's geopolitical position and local talent.
They also have an internal department that focuses on adapting innovation to the needs of the Mexican population, including applications, treatments and clinical trials. The company has invested in the remodeling of its Naucalpan plant between 2014 and 2017, with an investment of more than 150 million pesos, and primarily produces gastroenterology products in Mexico.
Takeda is the only subsidiary of the 80 that the company has worldwide with a complete operation in Mexico. The company employs about 450 people in its corporate offices and manufacturing plant and makes annual investments of around 40 million dollars in the country.
In addition, they serve around 10 million patients, since their highly specialized products have long-lasting patents and fit the health ecosystem of Mexico.
Information from: Milenio
Receive all industry news in our weekly Newsletter Scientific Dialectics.